Recent expansions of novel strategies towards the drug targeting into the brain
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The treatment of central nervous system (CNS) disorders always remains a challenge for the researchers. The presence of various physiological barriers, primarily the blood-brain barrier (BBB) limits the accessibility of the brain and hinders the efficacy of various drug therapies. Hence, drug targeting to the brain, particularly to the diseased cells by circumventing the physiological barriers is essential to develop a promising therapy for the treatment of brain disorders. Presently, the investigations emphasize the role of different nanocarrier systems or surface modified target specific novel carrier system to improve the efficiency and reduce the side effects of the brain therapeutics. Such approaches supposed to circumvent the BBB or have the ability to cross the barrier function and thus increases the drug concentration in the brain. Although the efficacy of novel carrier system depends upon various physiological factors like active efflux transport, protein corona of the brain, stability, and toxicity of the nanocarrier, physicochemical properties, patient-related factors and many more. Hence, to develop a promising carrier system, it is essential to understand the physiology of the brain and BBB and also the other associated factors. Along with this, some alternative route like direct nose-to-brain drug delivery can also offer a better means to access the brain without exposure of the BBB. In this review, we have discussed the role of various physiological barriers including the BBB and blood-cerebrospinal fluid barrier (BCSFB) on the drug therapy and the mechanism of drug transport across the BBB. Further, we discussed different novel strategies for brain targeting of drug including, polymeric nanoparticles, lipidic nanoparticles, inorganic nanoparticles, liposomes, nanogels, nanoemulsions, dendrimers, quantum dots, etc. along with the intranasal drug delivery to the brain. We have also illustrated various factors affecting the drug targeting efficiency of the developed novel carrier system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Nanoparticle Size on In Vivo Pharmacokinetics and Cellular Interaction
Hoshyar, N., Gray, S., Han, H., & Bao, G. (2016) · Nanomedicine · doi:10.2217/nnm.16.5 · Cited by 1,990
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791 · cited 1×
“It delayed the circulation time and distribution of the nanoparticles and affected the drug release pattern.(134) Sometimes, it also hinders the targeting ability of the system by covering the targeting ligand and thus, prevents the interaction between the ligand and target receptor.”
BackgroundEvolving Knowledge of Sex Differences in Brain Structure, Function, and Chemistry
Cosgrove, K. P., Mazure, C. M., & Staley, J. K. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.001 · Cited by 996 · cited 1×
“It senses the environment and surrounding stimulus; make decisions; process, controls and integrate all the information; develop thoughts, feelings, and plans; and store the memories of events throughout the life.(2) The Brain is shielded by various physiological barriers like blood–brain barrier (BBB) and blood-cereb…”
BackgroundMechanism of intranasal drug delivery directly to the brain
Crowe, T. P., Greenlee, M. H. W., Kanthasamy, A. G., & Hsu, W. H. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.025 · Cited by 721
Priller, J., Flügel, A., Wehner, T., Boentert, M., Haas, C. A., Prinz, M., Fernández-Klett, F., Prass, K., Bechmann, I., de Boer, B. A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1356 · Cited by 637
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Self-citationBlood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549
Strategies to advance translational research into brain barriers
Neuwelt, E., Abbott, N. J., Abrey, L., Banks, W. A., Blakley, B., Davis, T., Engelhardt, B., Grammas, P., Nedergaard, M., Nutt, J., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70326-5 · Cited by 474
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430 · cited 3×
“(BCSFB) which regulates the entry of foreign particles to the brain, protect it from the toxins and other harmful stimuli and maintain the homeostasis of the brain.(3)”
BackgroundVieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Progress in brain targeting drug delivery system by nasal route
Khan, A. R., Liu, M., Khan, M. W., & Zhai, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.001 · Cited by 402 · cited 1×
“Together with the drug targeting ability nanoparticle also promote the drug permeation through nasal mucosa, increases the brain bioavailability of the drug, protects the drug enzymatic degradation and increases the drug retention time in the nasal cavity (chitosan nanoparticle).(73,74) Kuo et al (2019) targeted the c…”
BackgroundTargeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Current approaches to enhance CNS delivery of drugs across the brain barriers
Lu, C.-T., Zhao, Y.-Z., Wong, H. L., Cai, J., Peng, L., & Tian, X.-Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61288 · Cited by 350
Drug transport in brain via the cerebrospinal fluid.
Pardridge, W. M. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-7 · Cited by 316
Yang, Z., Zhang, Y., Yang, Y., Sun, L., Han, D., Li, H., & Wang, C. (2010) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.11.007 · Cited by 311 · cited 1×
“However, the brain targeting ability of inorganic nanoparticles is hindered by its toxicity, poor drug release profile and non-biodegradability.(88)”
BackgroundNanoemulsions for “Nose-to-Brain” Drug Delivery
Bonferoni, M. C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., & Giunchedi, P. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020084 · Cited by 269
Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders
Qosa, H., Miller, D. S., Pasinelli, P., & Trotti, D. (2015) · Brain Research · doi:10.1016/j.brainres.2015.07.005 · Cited by 249 · cited 1×
“The ABC transporter or ATP-binding cassette transporter is recognized as the protein superfamilies present in almost all the living organisms.(30) The P-glycoprotein (P-gp) is the key element of ABC efflux transporter which actively regulates the outflux of many lipophilic drugs across the BBB.”
BackgroundAlexander, A., Ajazuddin, Khan, J., Saraf, S., & Saraf, S. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.07.005 · Cited by 249
Self-citationLiposome delivery systems for the treatment of Alzheimer’s disease
Ross, C., Taylor, M., Fullwood, N., & Allsop, D. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s183117 · Cited by 198 · cited 1×
“to assist the drug targeting to the brain.(51) For example; H102 peptide-loaded liposome was developed by Zheng”
BackgroundTheranostic applications of nanoparticles in neurodegenerative disorders
Ramanathan, S., Archunan, G., Sivakumar, M., Tamil Selvan, S., Fred, A. L., Kumar, S., Gulyás, B., & Padmanabhan, P. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s149022 · Cited by 161 · cited 1×
“Together with the drug targeting ability nanoparticle also promote the drug permeation through nasal mucosa, increases the brain bioavailability of the drug, protects the drug enzymatic degradation and increases the drug retention time in the nasal cavity (chitosan nanoparticle).(73,74) Kuo et al (2019) targeted the c…”
BackgroundChu, L., Wang, A., Ni, L., Yan, X., Song, Y., Zhao, M., Sun, K., Mu, H., Liu, S., Wu, Z., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1494226 · Cited by 127
Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion
Abdou, E. M., Kandil, S. M., & Miniawy, H. M. F. E. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.030 · Cited by 124 · cited 1×
“They assessed the brain targeting efficiency of nanoemulsion and observed the mucoadhesive intranasal nanoemulsion significantly enhances the drug permeability, AUC and bioavailability in the brain.(103)”
BackgroundAl-azzawi, S., Masheta, D., Guildford, A. L., Phillips, G., & Santin, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103224 · Cited by 49 · cited 1×
“materials, consists of metalloid crystal core and nonreactive metallic shell which covers the crystalline core.(115,116) The long-term photostability, high brightness, size-tunable narrow emission spectra make it a promising diagnostic tool.”
BackgroundKuo, Y.-C., & Chou, P.-R. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24081 · Cited by 43
Cited by
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
“, which have shown great potential than previous delivery systems, developed by the nanotechnological approach (Rajadhyaksha et al., 2011; Wong et al., 2012; Ozkizilcik et al., 2017; Alexander et al., 2019).”
BackgroundStimuli-responsive In situ gelling system for nose-to-brain drug delivery
Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Gupta, U., Kesharwani, P., Ravichandiran, V., Kumar, P., Naidu, V. G. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.044 · Cited by 298
Self-citationEnhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Choudhury, S. P., Bano, S., Sen, S., Suchal, K., Kumar, S., Nikolajeff, F., Dey, S. K., & Sharma, V. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00324-9 · Cited by 52
Kumar, S., Yadav, A., Verma, R. K., Kumar, A., Gupta, P. K., & Shukla, R. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00386 · Cited by 14
Metadata
- Authors
- Alexander, A., Agrawal, M., Uddin, A., Siddique, S., Shehata, A. M., Shaker, M. A., Ata Ur Rahman, S., Abdul, M. I. M., & Shaker, M. A.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2019-07
- Volume
- Volume 14
- Pages
- 5895-5909
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2964787817
- Cited by
- 157
- References
- 24
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.